Enliven Therapeutics Q2 net loss widens to $32.5 million; cash $895.2 million
Enliven Therapeutics reported a second-quarter 2026 net loss of $32.5 million, up from $25.3 million a year earlier, as research and development expenses rose to $29.0 million from $21.5 million. The company had $895.2 million in cash, cash equivalents and marketable securities at June 30, 2026, which it expects to provide cash runway into 2030. It also said it reached alignment with the FDA on key components of the Phase 3 ENABLE-2 trial design for ELVN-001, with the Phase 3 trial expected to start in the second half of 2026.
Key points
- Net loss of $32.5 million in Q2 2026 vs. $25.3 million in Q2 2025; net loss per share of $0.49 in both periods
- R&D expenses $29.0 million vs. $21.5 million; G&A expenses $8.2 million vs. $7.1 million
- Cash, cash equivalents and marketable securities of $895.2 million at June 30, 2026, up from $462.6 million at December 31, 2025
- FDA selected 80 mg once daily as the recommended Phase 3 dose; End-of-Phase 2 meeting anticipated in Q3 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.